Shares in biotech firm Edge Therapeutics (NASDAQ:EDGE) rocketed as it announced the full set of results from its North American Phase I/II study of its EG-1962 treatment for NEWTON will be presented at the International Stroke Conference 2016.
The event will be held on February 17-19 at the Los Angeles Convention Center.
Shares in the company jumped around 13.5% to US$7.72 on the news.
The clinical-stage biotech firm is developing novel hospital-based therapies in the management of acute, life-threatening conditions.
Edge's lead product candidate, EG-1962, is in development to treat patients who have suffered a rare type of stroke known as aneurysmal subarachnoid haemorrhage, which can be the results of a ruptured brain aneurysm.
The data is from a Phase I/II trial, which, simply put was used to test whether microparticles can be used to treat patients who have suffered from the rare type of stroke